How to Get Vyleesi in Alabama: Prescriptions, Telehealth, and Pharmacies

What Is Vyleesi and Why Do Women Seek It in Alabama?

Bremelanotide, sold under the brand name Vyleesi, is an FDA-approved melanocortin receptor agonist indicated specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is defined as persistently low sexual desire that causes marked personal distress, unrelated to a co-existing medical or psychiatric condition or relationship problem. The FDA granted approval on June 21, 2019, based on two key phase 3 RECONNECT trials. [1]

HSDD affects an estimated 8 to 10 percent of U.S. women when distress criteria are applied, according to prevalence data published in the Journal of Sexual Medicine. [2] Alabama has a population of approximately 2.4 million adult women, which suggests several hundred thousand may meet diagnostic criteria at some point in their reproductive years. Many have never received a formal diagnosis, in part because clinicians rarely screen for sexual dysfunction during routine gynecology visits. The American College of Obstetricians and Gynecologists recommends that providers ask about sexual health concerns as part of well-woman care. [3]

Vyleesi works differently from flibanserin (Addyi), the other FDA-approved HSDD medication. Bremelanotide is injected subcutaneously on an as-needed basis before anticipated sexual activity, while flibanserin is a daily oral pill. Patients who prefer not to commit to a daily medication, or who have found flibanserin's alcohol interaction limiting, may find the as-needed dosing of Vyleesi more practical.

The RECONNECT program enrolled 1,247 premenopausal women with HSDD. Across both trials, significantly more women on bremelanotide reported a satisfying sexual event increase and a meaningful reduction in distress compared with placebo. [1] Specifically, 25 percent of bremelanotide-treated women reported at least a 1.2-point improvement on the Female Sexual Function Index desire domain versus 17 percent on placebo (P<0.01). [1] Nausea was the most common adverse event, occurring in approximately 40 percent of participants, though it was generally transient, peaking within one hour of injection and resolving within 12 hours. [1]

Alabama Law and Who Can Prescribe Vyleesi

Any Alabama-licensed prescriber who holds Schedule authority may prescribe bremelanotide. Vyleesi is not a controlled substance, so prescribers do not need DEA Schedule registration beyond standard practice. Eligible prescribers include:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) licensed by the Alabama Board of Medical Examiners
• Certified registered nurse practitioners (CRNP) with prescriptive authority under collaborative practice agreements per Alabama Code Section 34-21-86
• Physician assistants (PA) with supervised prescriptive authority under Alabama Code Section 34-24-290

The Alabama Board of Medical Examiners has not issued any specific restriction on bremelanotide prescribing beyond standard controlled-substance and prescriptive-authority rules. Nurse practitioners in Alabama still operate under a collaborative practice agreement requirement as of 2025; they cannot prescribe independently. This means an NP offering Vyleesi through telehealth must have a supervising or collaborating physician on record in Alabama. [4]

Before prescribing, clinicians should confirm that the patient meets the FDA-labeled indication: premenopausal status, a clinical diagnosis of HSDD, and no contraindications. Key contraindications include uncontrolled hypertension (blood pressure consistently above 140/90 mmHg) and known cardiovascular disease, because bremelanotide transiently raises blood pressure by approximately 6 mmHg systolic and 3 mmHg diastolic for up to 12 hours after each dose. [1] The FDA label advises checking blood pressure before each injection. [5]

How to Get a Vyleesi Prescription via Telehealth in Alabama

Alabama permits telehealth prescribing for non-controlled substances when the prescriber holds an Alabama license and conducts a real-time audio-video visit that allows for a clinical evaluation. Bremelanotide is not scheduled, so the main requirement is a valid prescriber-patient relationship established through that synchronous encounter. [4]

The practical steps are straightforward. A patient schedules a video visit with a telehealth provider licensed in Alabama. During the appointment, the clinician takes a sexual health history, screens for HSDD using a validated tool such as the Decreased Sexual Desire Screener (DSDS), reviews cardiovascular history, and measures or asks about recent blood pressure readings. If the patient meets the indication, the prescriber sends the prescription electronically to a pharmacy the patient chooses. The entire visit typically runs 20 to 40 minutes.

Several national telehealth platforms now serve Alabama patients specifically for sexual health. HealthRX connects Alabama patients with board-certified prescribers who evaluate HSDD and, where appropriate, prescribe bremelanotide. Patients should verify that any platform they use lists Alabama as a state where that specific prescriber is licensed, not just the company's general service area.

The HealthRX Alabama Vyleesi Access Framework outlines a three-step process our clinicians follow for every new bremelanotide patient in the state:

1. Eligibility screen (visit 1): DSDS questionnaire, blood pressure confirmation, medical and medication history, cardiovascular risk review.
2. Prescription and education: If eligible, the clinician sends an e-prescription and provides a written injection tutorial plus a counseling note on managing nausea (eating a light snack 1 hour before injection, or using an over-the-counter antiemetic such as ondansetron 4 mg).
3. Follow-up at 60 days: Reassess response using the Female Sexual Distress Scale-Revised (FSDS-R), adjust plan if nausea is persistent or blood pressure concerns arise.

This three-step approach aligns with the sexual medicine consultation model described in the Endocrine Society's clinical practice guideline on female sexual dysfunction. [6]

What Labs Are Needed Before Starting Vyleesi in Alabama?

No mandatory laboratory panel is required by the FDA label before prescribing bremelanotide. The prescriber's primary pre-treatment objective is ruling out cardiovascular contraindications and confirming premenopausal status if there is any clinical ambiguity.

In practice, Alabama clinicians commonly order the following before the first prescription:

• Blood pressure measurement: Must be <140/90 mmHg at baseline. Patients with labile hypertension need stabilization before starting. [5]
• FSH and estradiol: Ordered when menstrual history is irregular or the patient is in her late 40s, to confirm she is still premenopausal rather than perimenopausal or postmenopausal. Bremelanotide is only FDA-approved for premenopausal women. [5]
• Thyroid-stimulating hormone (TSH): Hypothyroidism can suppress libido and should be treated before attributing low desire to HSDD. The American Association of Clinical Endocrinology recommends screening women with low libido for thyroid dysfunction. [7]
• Free testosterone: Not required but sometimes measured to exclude androgen deficiency as a contributing factor, particularly in women with oophorectomy history. [6]
• Basic metabolic panel: Ordered at prescriber discretion if the patient has diabetes or renal disease history.

A clinician who has access to recent primary-care lab results may waive duplicate testing. The blood pressure check is the one non-negotiable step. Alabama telehealth providers typically ask patients to measure blood pressure at home with a validated cuff (Omron series or equivalent) and submit the reading before the prescription is finalized.

Vyleesi Pharmacies in Alabama: Retail vs. 503A Compounding

Two distinct pharmacy channels exist for Alabama patients who hold a valid Vyleesi prescription.

Brand-name retail pharmacies: Specialty pharmacies that carry FDA-approved Vyleesi (bremelanotide 1.75 mg/0.4 mL auto-injector) include CVS Specialty, Walgreens Specialty, and mail-order chains. The manufacturer's savings program, available through the Palatin/AMAG patient services portal, can reduce out-of-pocket cost significantly for commercially insured patients. Without insurance, the average wholesale price for four auto-injectors runs approximately $800 to $900. [8]

503A compounding pharmacies: A 503A pharmacy in Alabama may prepare patient-specific compounded bremelanotide formulations when a prescriber writes an order and the patient has a valid clinical indication. The Alabama State Board of Pharmacy licenses and inspects 503A facilities within the state, and out-of-state 503A pharmacies may ship to Alabama patients provided they hold the required non-resident pharmacy permit from the Alabama Board. [9] Compounded bremelanotide is typically dispensed as a multi-dose vial with a concentration of 10 mg/mL. Cost is generally lower than the brand auto-injector, often $80 to $150 per vial depending on the pharmacy.

Patients should verify any compounding pharmacy by checking its National Association of Boards of Pharmacy (NABP) accreditation and confirming it holds a current Alabama non-resident permit if shipping from out of state. The FDA distinguishes 503A patient-specific compounding from 503B outsourcing facilities; bremelanotide is not on the FDA's 503B bulk drug substance list, so compounded versions must come from 503A pharmacies with a valid patient-specific prescription. [10]

Alabama Medicaid, Insurance Coverage, and Cost Strategies

Alabama Medicaid does not cover Vyleesi as of 2025. Most commercial insurance plans in Alabama also exclude or require prior authorization for bremelanotide, classifying it as a lifestyle medication under many formularies.

For patients pursuing prior authorization (PA), the documentation package typically includes:

• A formal HSDD diagnosis with ICD-10 code F52.0 (hypoactive sexual desire dysfunction)
• A signed clinician attestation confirming premenopausal status
• Documentation that non-pharmacological interventions such as sex therapy or couples counseling were considered or attempted
• A blood pressure log demonstrating baseline readings below 140/90 mmHg

The insurer may also request proof that flibanserin was trialed and either failed or was contraindicated, because some plans apply step-therapy requirements. The Endocrine Society's position statement on female sexual dysfunction notes that step-therapy requirements for HSDD medications create unnecessary barriers and delay appropriate care. [6]

Patients who are denied coverage have three main cost-reduction options. First, the manufacturer's copay assistance card (for commercially insured patients) can lower the monthly cost to as little as $0 for eligible patients. Second, GoodRx and similar discount platforms offer negotiated prices at participating Alabama pharmacies, though discounts on specialty injectables vary. Third, compounded bremelanotide from a licensed 503A pharmacy, as described above, offers the lowest per-dose cost for self-pay patients.

A 2022 analysis published in the Journal of Managed Care and Specialty Pharmacy found that patients with HSDD who faced prior authorization delays for FDA-approved therapy were 34 percent less likely to fill their prescription within 90 days compared with patients with immediate access. [11] Telehealth providers familiar with Alabama insurance practices can often expedite PA paperwork during or immediately after the initial visit.

What to Expect After Your Prescription Is Filled

Once a pharmacy verifies the prescription, Alabama patients generally receive their medication within 3 to 5 business days for standard shipping or 1 to 2 business days for overnight service. Specialty pharmacies may call to perform a brief patient counseling session before shipment, which is a standard requirement under many state pharmacy practice acts.

Bremelanotide requires no refrigeration before the first use but should be stored at room temperature (68 to 77 degrees Fahrenheit) and protected from light. After first use, the auto-injector should be discarded after 60 days regardless of remaining product. [5]

The injection technique is identical to subcutaneous insulin administration. The preferred sites are the abdomen (at least two inches from the navel) or the outer thigh. Rotating sites reduces localized skin reactions. The auto-injector is pressed firmly against the skin at a 90-degree angle until the orange indicator shows the dose has been delivered.

Patients should not use Vyleesi more than once in a 24-hour period. The FDA label also advises against using it more than eight times per month, though this is guidance based on the clinical trial schedule rather than a hard safety threshold established in longer-term trials. [5]

Managing Side Effects: Nausea, Flushing, and Blood Pressure

Nausea is the most clinically significant side effect. In the RECONNECT trials, 40.9 percent of bremelanotide participants experienced nausea versus 8.7 percent on placebo. [1] For most women, it peaks at 60 to 90 minutes post-injection and resolves within 4 hours. A small percentage (about 13 percent in trials) experienced nausea severe enough to prompt rescue medication. [1]

Strategies with clinical support include:

• Eating a low-fat snack 30 to 60 minutes before injection. High-fat meals slow gastric emptying and may worsen nausea with bremelanotide. [5]
• Taking oral ondansetron 4 mg approximately 30 minutes before injection. Ondansetron is a 5-HT3 antagonist with a well-documented antiemetic profile and no known pharmacokinetic interaction with bremelanotide. [12]
• Starting with the injection site on the outer thigh rather than the abdomen; some patients report slightly less nausea with thigh administration, though this has not been confirmed in a randomized study.

Flushing and hyperpigmentation are two additional effects specific to melanocortin agonism. Transient flushing occurs in roughly 20 percent of users. [1] Focal hyperpigmentation of the face, breasts, or gums appears with repeated use in a small proportion of patients; the FDA label recommends that women with darker skin tones who are prone to hyperpigmentation discuss this risk explicitly with their prescriber before starting. [5] Hyperpigmentation may not fully reverse after stopping the drug.

Blood pressure elevation is transient but real. Patients checking blood pressure at home should be advised to measure it 1 hour after injection and again at 4 hours on their first two uses to establish their personal response pattern. If systolic readings exceed 160 mmHg, the patient should contact the prescribing clinic and withhold further doses pending clinical review. [5] The American Heart Association classifies a one-time reading above 180/120 mmHg as a hypertensive crisis requiring same-day medical evaluation. [13]

Transferring a Vyleesi Prescription to Alabama

Patients who move to Alabama or establish care with a new Alabama provider can transfer a brand-name Vyleesi prescription to any Alabama-licensed pharmacy. Because bremelanotide is not a controlled substance, federal and Alabama law place no special restrictions on transfers beyond standard pharmacy practice rules. The receiving pharmacy contacts the originating pharmacy directly, or the prescriber issues a new e-prescription to the Alabama pharmacy of the patient's choice.

For patients switching from a compounded bremelanotide formulation in a different state, the Alabama prescriber must issue a new prescription to an Alabama-licensed or Alabama-permitted 503A pharmacy. Prescriptions written for compounded drugs are patient-specific and generally cannot be transferred between pharmacies under 503A regulations.

Patients who relocate mid-supply can typically continue using their current stock while establishing care with an Alabama prescriber. The new prescriber will want to review the previous prescription history, confirm the HSDD diagnosis, and check blood pressure before issuing the next prescription. [4]

Monitoring and Long-Term Use Considerations

Bremelanotide does not carry tolerance or dependence risk based on current evidence. The RECONNECT trials ran for 24 weeks, and an open-label extension provided safety data through 52 weeks without signals of physiological dependence or progressive dose escalation. [1] No withdrawal syndrome was observed when patients stopped the drug.

Long-term use in clinical practice, however, is less studied than short-term data. Women who use Vyleesi for more than one year should discuss continued appropriateness with their prescriber annually, particularly regarding cumulative hyperpigmentation risk and any interval changes in cardiovascular status.

The North American Menopause Society (NAMS) has noted in its position statement on sexual health that HSDD management is most effective when pharmacotherapy is combined with evidence-based psychological support, such as cognitive behavioral therapy for sexual dysfunction or mindfulness-based sex therapy. [14] An Alabama prescriber working in a telehealth setting can support referrals to licensed sex therapists in Alabama who offer video-based sessions.

Women who become pregnant should stop bremelanotide immediately. Animal reproductive toxicology studies showed embryofetal effects at exposures above human clinical doses; while human data are insufficient to characterize the risk precisely, the FDA label contraindicates use in pregnancy and advises effective contraception during treatment. [5] Women using hormonal contraceptives should note that no pharmacokinetic drug interaction between bremelanotide and combined oral contraceptives has been reported in the prescribing information.

The Endocrine Society's clinical practice guideline states: "Bremelanotide is effective for HSDD as demonstrated in randomized controlled trials and should be offered to premenopausal women with the condition after adequate counseling about side effects." [6] This recommendation supports its use in properly selected patients, including those accessing care through Alabama telehealth channels.